Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides.

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Abstract Text:

The therapeutic potential of cytolytic peptides is plagued by nonspecificity and enzymatic degradation. We report the first stable incorporation of melittin (a 26 amino acid amphipathic peptide) into an outer lipid monolayer of perfluorocarbon nanoparticles. Melittin binds avidly to the nanoparticles (dissociation constant approximately 3.27 nM) and retains its pore-forming activity after contact-mediated delivery to model bilayer membrane (liposomes) thereby demonstrating the effectiveness of perfluorocarbon nanoparticles as unique nanocarriers for cytolytic peptides.

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Nano letters

VOLUME: 8

Page Numbers: 1131-6

Journal Abbreviation:

ISSN: 1530-6984

DAY: 27

MONTH: 02

YEAR: 2008

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101088070

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides.

AFFILIATION: Departments of Biomedical Engineering, Cardiology, and Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110 paul@cellbiology.wustl.edu, saw@wuphys.wustl.edu.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Nano Lett

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides Related Publications

• 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons.
• 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles.
• Contrast agents for MRI.
• Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS.
• Experimental determination of phase velocity of perfluorocarbons: Applications to targeted contrast agents.
• Exploiting lipid raft transport with membrane targeted nanoparticles: A strategy for cytosolic drug delivery.
• High-frequency ultrasound detection of the temporal evolution of protein cross linking in myocardial tissue.
• Molecular Imaging by Cardiovascular MR.
• Nanomedicine opportunities in cardiology.
• Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery.
• Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging.
• Sensitive ultrasonic detection of dystrophic skeletal muscle in patients with duchenne muscular dystrophy using an entropy-based signal receiver.
• Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides.
• Targeted ultrasonic contrast agents for molecular imaging and therapy.
• Thromboembolism in patients undergoing total knee arthroplasty with epidural analgesia.